These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 7720083

  • 81. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide.
    Nardelli B, Tam JP.
    Immunology; 1993 Jul; 79(3):355-61. PubMed ID: 8104882
    [Abstract] [Full Text] [Related]

  • 82. Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.
    Wagner R, Deml L, Wolf H.
    Antibiot Chemother (1971); 1994 Jul; 46():48-61. PubMed ID: 7826039
    [No Abstract] [Full Text] [Related]

  • 83. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.
    Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, Sempala SD, Giraldo G, Buonaguro FM.
    Antiviral Res; 2002 Jun; 54(3):189-201. PubMed ID: 12062391
    [Abstract] [Full Text] [Related]

  • 84.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 85.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 86.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 87.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 88.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 89. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants.
    Peter K, Men Y, Pantaleo G, Gander B, Corradin G.
    Vaccine; 2001 Jul 20; 19(30):4121-9. PubMed ID: 11457536
    [Abstract] [Full Text] [Related]

  • 90. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses.
    Kato H, Bukawa H, Hagiwara E, Xin KQ, Hamajima K, Kawamoto S, Sugiyama M, Sugiyama M, Noda E, Nishizaki M, Okuda K.
    Vaccine; 2000 Jan 18; 18(13):1151-60. PubMed ID: 10649615
    [Abstract] [Full Text] [Related]

  • 91. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response.
    Morris CB, Thanawastien A, Sullivan DE, Clements JD.
    Vaccine; 2001 Oct 12; 20(1-2):12-5. PubMed ID: 11567739
    [Abstract] [Full Text] [Related]

  • 92.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 93.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 94. X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.
    Hovav AH, Santosuosso M, Bivas-Benita M, Plair A, Cheng A, Elnekave M, Righi E, Chen T, Kashiwagi S, Panas MW, Xiang SH, Furmanov K, Letvin NL, Poznansky MC.
    J Virol; 2009 Nov 12; 83(21):10941-50. PubMed ID: 19692474
    [Abstract] [Full Text] [Related]

  • 95. Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides.
    Eriksson K, Horal P, Svennerholm B, Jeansson S, Vahlne A, Holmgen J, Czerkinsky C.
    Vaccine; 1993 Nov 12; 11(8):859-65. PubMed ID: 7689284
    [Abstract] [Full Text] [Related]

  • 96. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.
    Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA.
    Nature; 1990 Apr 26; 344(6269):873-5. PubMed ID: 2184369
    [Abstract] [Full Text] [Related]

  • 97. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates.
    Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR.
    AIDS Res Hum Retroviruses; 2008 Feb 26; 24(2):271-81. PubMed ID: 18260780
    [Abstract] [Full Text] [Related]

  • 98. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
    Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W.
    Vaccine; 2001 Apr 30; 19(23-24):3033-42. PubMed ID: 11311997
    [Abstract] [Full Text] [Related]

  • 99. Effects of influenza virus-specific cytotoxic T-lymphocyte responses induced by a synthetic nucleoprotein peptide on the survival of mice challenged with a lethal dose of virus.
    Sastry KJ, Bender BS, Bell W, Small PA, Arlinghaus RB.
    Vaccine; 1994 Nov 30; 12(14):1281-7. PubMed ID: 7856292
    [Abstract] [Full Text] [Related]

  • 100. Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates.
    Rubinstein A, Mizrachi Y, Pettoello-Mantovani M, Lenz J, Liu GQ, Rubinstein Y, Goldstein H, Yust I, Burke M, Vardinon N, Spirer Z, Cryz SJ.
    J Acquir Immune Defic Syndr; 1999 Dec 15; 22(5):467-76. PubMed ID: 10961608
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.